GSK (GSK) Set to Announce Quarterly Earnings on Wednesday

GSK (NYSE:GSK) will be issuing its quarterly earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.95 per share for the quarter. GSK has set its FY 2024 guidance at 1.640-1.690 EPS.

GSK (NYSE:GSK) last released its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.04). The firm had revenue of $10 billion during the quarter, compared to analyst estimates of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

GSK Stock Up 1.6 %

NYSE GSK opened at $41.24 on Wednesday. The stock has a fifty day moving average of $41.88 and a 200-day moving average of $38.90. The stock has a market capitalization of $85.47 billion, a P/E ratio of 13.70, a price-to-earnings-growth ratio of 1.40 and a beta of 0.64. GSK has a 52 week low of $33.33 and a 52 week high of $43.84. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd were given a $0.3564 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 annualized dividend and a dividend yield of 3.46%. The ex-dividend date was Thursday, February 22nd. GSK’s dividend payout ratio (DPR) is currently 52.82%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on GSK shares. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Jefferies Financial Group upgraded GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Finally, Morgan Stanley started coverage on GSK in a report on Tuesday, January 23rd. They set an “equal weight” rating on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.